Conflict of interest statement: There are no conflict of interest.180. South Asian J Cancer. 2018 Apr-Jun;7(2):127-131. doi: 10.4103/sajc.sajc_118_18.Practical consensus recommendations on management of triple-negative metastaticbreast cancer.Rangarao R(1), Smruti BK(2), Singh K(3), Gupta A(4), Batra S(1), Choudhary RK(5),Gupta A(6), Sahani S(7), Kabra V(8), Parikh PM(9), Aggarwal S(10).Author information: (1)Department of Medical Oncology, Max Hospital, New Delhi, India.(2)Dept of Medical Oncology, Bombay Hospital, Mumbai, Maharashtra, India.(3)Department of Radiation Oncology, MAMC, New Delhi, India.(4)Department of Radiation Oncology, Safdarjung Hospital, New Delhi, India.(5)Department of Medical Oncology, Metro Cancer Center, New Delhi, India.(6)Department of Radiation Oncology, GMC, Jammu and Kashmir, India.(7)Department of Surgical Oncology, Indraprastha Apollo Hospital, New Delhi,India.(8)Department of Surgical Oncology, Manipal Super Specialty Hospital, Gurugram,Haryana, India.(9)Department of Oncology, Shalby Cancer and Research Institute, Mumbai,Maharashtra, India.(10)Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India.Patients with breast cancer along with metastatic estrogen and progesteronereceptor (ER/PR)- and human epidermal growth factor receptor 2 (HER2)-negativetumors are referred to as having metastatic triple-negative breast cancer (mTNBC)disease. Resistance to current standard therapies such as anthracyclines ortaxanes limits the available options for previously treated patients withmetastatic TNBC to a small number of non-cross-resistant regimens, and there iscurrently no preferred standard chemotherapy. Clinical experience suggests thatmany women with triple-negative metastatic breast cancer (MBC) relapse quickly.Expert oncologist discussed about new chemotherapeutic strategies and agents usedin treatment of mTNBC and the expert group used data from published literature,practical experience and opinion of a large group of academic oncologists toarrive at this practical consensus recommendations for the benefit of communityoncologists.DOI: 10.4103/sajc.sajc_118_18 PMCID: PMC5909290PMID: 29721479 